Celldex Therapeutics, Inc. (CLDX) SEC Filings & Earnings Calls

Clinical trial outcome risk; no efficacy/safety data provided in excerpt.

“announcing results from its two Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials” · word for word

Phase 2 PN failure highlights pipeline risk.

“Phase 2 PN study did not meet endpoints; program discontinued.”

Clinical Trial Failure

“In July 2026, we shared topline results that showed the trial did not meet primary or key secondary endpoints at Week 12 at either dose level evaluated.” · word for word

Dependence on Lead Program

“Barzolvolimab/Anti-KIT Program $54,946 for the three months ended June 30, 2026, representing 81% of total R&D expense.”

Key executive departure may cause temporary uncertainty, but transition plan mitigates risk.

“CFO retirement with planned transition, search for successor initiated.”

Potential dilution from increased share reserve, though typical for biotech incentive plans.

“increase in the number of the shares reserved for issuance thereunder by 3,400,000 shares to 12,900,000 shares” · word for word

Clinical trial failure risk for barzolvolimab and CDX-622.

“Topline data expected in Q4 2026; Phase 2 data in PN and AD expected summer/late 2026.”

Clinical trial failure risk

“Historically, the results from preclinical testing and early clinical trials (through Phase 2) have often not been predictive of results obtained in later clinical trials.” · word for word

Liquidity risk beyond 12 months

“The Company's ability to continue funding its planned operations beyond twelve months from the issuance date is also dependent on the timing and manner of payment of the future milestone under the Settlement Agreement.” · word for word

Dilution risk from capital raises

“Additional equity financings may be dilutive to the Company's stockholders.” · word for word

Clinical trial failure risk

“The company is a clinical-stage biotech with no approved products; barzolvolimab and CDX-622 are in Phase 3 and Phase 1, respectively.”

Dilution risk from equity plan increase

“Proposal to increase shares reserved under the 2021 Incentive Plan by 3,400,000 shares to 12,900,000 shares.”

Dilution risk from new share issuance; potential overhang if option exercised.

“Issuance of 10,345,000 shares plus option for 1,551,750 additional shares.”

NOL utilization limitation due to ownership changes

“Utilization of these NOLs depends on many factors, including our future income, which cannot be assured. In addition, utilization of our net operating loss and research and development credit carryforwards may be subject to substantial annual limitation due to ownership change limitations that have occurred previously or that could occur in the future provid” · word for word

Clinical trial failure risk

“Historically, the results from preclinical testing and early clinical trials (through Phase 2) have often not been predictive of results obtained in later clinical trials.” · word for word

Competition from established players

“We have many competitors in the U.S. and abroad.” · word for word

Dependence on key personnel

“We depend greatly on the intellectual capabilities and experience of our key executives and scientists, and the loss of any of them could affect our ability to develop our products.” · word for word

Supply chain and geopolitical disruptions

“Disruptions in the global economy and supply chains may have a material adverse effect on our business, financial condition and results of operations.” · word for word

Clinical trial failure risk for barzolvolimab in multiple indications

“Phase 3 CSU data expected Q4 2026; Phase 2 PN and AD data expected 2026; Phase 1 CDX-622 data expected Q3 2026”

Regulatory and commercial execution risk for BLA filing and launch

“BLA submission planned for 2027; company preparing for commercialization”

Clinical Trial Failure Risk

“Our drug candidates are still in development stages and may fail to demonstrate safety and efficacy in clinical trials.”

Financing Risk

“We may need to raise additional capital to fund our operations, and such financing may not be available on acceptable terms.”

Regulatory Approval Risk

“Regulatory approval is required before we can market our drug candidates as therapeutic products.” · word for word

Dependence on Key Product Candidate

“Our business is highly dependent on the success of barzolvolimab, our most advanced product candidate.”

No revenue; net loss expected; reliance on pipeline success.

“Press release reports financial results for Q3 2025; no revenue mentioned; typical for development-stage biotech.”